JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Azo-linked 5-ASA-coumarin prodrug: Fluorescent tracking for colonic drug release in UC treatment

  • 0Department of Pain, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and BrainHealth), Wenzhou Medical University, Zhejiang, China.
Talanta +

|

November 28, 2024

|

November 28, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new theranostic prodrug system enables simultaneous delivery and tracking of 5-aminosalicylic acid (5-ASA) for ulcerative colitis (UC) treatment. This system allows real-time monitoring of drug release and biodistribution for personalized medicine.

Area Of Science

  • Pharmaceutical Sciences
  • Biomedical Engineering
  • Drug Delivery Systems

Background

  • Theranostic prodrugs are crucial for real-time, non-invasive monitoring of drug release and biodistribution.
  • Optimizing therapeutic efficacy and guiding personalized medication requires advanced drug delivery systems.

Purpose Of The Study

  • To develop a colon-targeted theranostic prodrug system for simultaneous delivery and tracking of 5-aminosalicylic acid (5-ASA).
  • To enable real-time monitoring of drug release and biodistribution for ulcerative colitis (UC) treatment.

Main Methods

  • A theranostic prodrug (P1) was synthesized, linking 5-ASA to a fluorescent reporter (7-AMC) via an azo bond.
  • P1 was encapsulated in polymeric micelles (PM) for enhanced solubility and targeted delivery to inflamed colonic tissues.
  • In vitro studies assessed stability and biocompatibility; in vivo studies used a UC mouse model for efficacy and biodistribution tracking.

Main Results

  • The P1-loaded PM system demonstrated stability, biocompatibility, and selective activation in the colon.
  • Targeted delivery of 5-ASA to the inflamed colon was achieved, effectively reducing colitis symptoms.
  • In situ activation allowed real-time, non-invasive visualization of drug release and biodistribution.

Conclusions

  • The developed colon-targeted theranostic prodrug system offers a promising strategy for simultaneous 5-ASA therapy and tracking in UC.
  • This approach facilitates personalized medication and improved therapeutic outcomes through real-time monitoring.
  • The theranostic system provides valuable insights for optimizing drug delivery and treatment strategies.